108 related articles for article (PubMed ID: 22789729)
1. Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Vilas-Boas F; Gonçalves R; Sobrinho Simões M; Lopes J; Macedo G
Gastroenterol Hepatol; 2012 Oct; 35(8):560-6. PubMed ID: 22789729
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide-associated hepatitis: a case report.
Fowler R; Imrie K
Am J Hematol; 2001 Apr; 66(4):300-2. PubMed ID: 11279644
[TBL] [Abstract][Full Text] [Related]
3. Dramatic response of diffuse osteosclerosis secondary to multiple myeloma using thalidomide with melphalan and prednisolone.
Mohamed M; Brain T; Khalafallah A
J Clin Oncol; 2014 Aug; 32(23):e85-7. PubMed ID: 24516032
[No Abstract] [Full Text] [Related]
4. Thalidomide-induced severe hepatotoxicity.
Hanje AJ; Shamp JL; Thomas FB; Meis GM
Pharmacotherapy; 2006 Jul; 26(7):1018-22. PubMed ID: 16803426
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide-induced severe hepatotoxicity.
Dabak V; Kuriakose P
Cancer Chemother Pharmacol; 2009 Mar; 63(4):583-5. PubMed ID: 19083237
[No Abstract] [Full Text] [Related]
6. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H; Mariko Y; Shinichiro O; Kunihiko M; Yusuke T; Yasuo I
Eur J Haematol; 2006 Apr; 76(4):358-9. PubMed ID: 16519710
[No Abstract] [Full Text] [Related]
8. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
[TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide maintenance in multiple myeloma: certainties and controversies.
Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P
J Clin Oncol; 2009 Nov; 27(32):e186-7; author reply e188. PubMed ID: 19770366
[No Abstract] [Full Text] [Related]
11. [Multiple myeloma].
Iida S
Rinsho Ketsueki; 2012 Feb; 53(2):155-63. PubMed ID: 22450574
[No Abstract] [Full Text] [Related]
12. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
[No Abstract] [Full Text] [Related]
13. Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma.
Reed-Guy L; Hoteit MA; Garfall AL
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e337-e338. PubMed ID: 29907543
[No Abstract] [Full Text] [Related]
14. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Geng C; Hou J; Zhao Y; Ke X; Wang Z; Qiu L; Xi H; Wang F; Wei N; Liu Y; Yang S; Wei P; Zheng X; Huang Z; Zhu B; Chen WM
Am J Hematol; 2014 Nov; 89(11):1037-42. PubMed ID: 25092564
[TBL] [Abstract][Full Text] [Related]
16. Urinary cytology in multiple myeloma.
Patil S; Schwarer A; McLean C
Cytopathology; 2008 Apr; 19(2):130-1. PubMed ID: 17488260
[No Abstract] [Full Text] [Related]
17. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
18. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
19. [Chemotherapy for multiple myeloma].
Ishida T
Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).
Eom HS; Kim YK; Chung JS; Kim K; Kim HJ; Kim HY; Jin JY; Do YR; Oh SJ; Suh C; Seong CM; Kim CS; Lee DS; Lee JH
Ann Hematol; 2010 May; 89(5):489-97. PubMed ID: 20012045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
